Literature DB >> 28106106

Serous tubal intraepithelial neoplasia: the concept and its application.

Emily E K Meserve1, Jan Brouwer2, Christopher P Crum1.   

Abstract

In recent years it has become clear that many extra-uterine (pelvic) high-grade serous carcinomas (serous carcinomas) are preceded by a precursor lesion in the distal fallopian tube. Precursors range from small self-limited 'p53 signatures' to expansile serous tubal intraepithelial neoplasms that include both serous tubal epithelial proliferations (or lesions) of uncertain significance and serous tubal intraepithelial carcinomas. These precursors can be considered from three perspectives. The first is biologic underpinnings, which are multifactorial, and include the intersection of DNA damage with Tp53 mutations and disturbances in transcriptional regulation that increase with age. The second perspective is the morphologic discovery and classification of intraepithelial neoplasms that are intercepted early in their natural history, either incidentally or in risk-reduction surgeries for germline mutations. For the practicing pathologist, as well as the investigators, a distinction between a primary intraepithelial neoplasm and an intramucosal carcinoma must be made to avoid misinterpreting (or underestimating) the significance of these proliferations. The third perspective is the application of this information to intervention, devising strategies that will actually lower the ovarian cancer death rate by opportunistic salpingectomy, widespread comprehensive genetic screening and early detection. Central to this issue are the questions of (1) whether some STICs are metastatic, (2) whether lower-grade epithelial proliferations can invade prior to evolving into intraepithelial carcinoma, or (3) metastasize and become malignant elsewhere ('precursor escape'). An important caveat is the persistent and unsettling reality that many high-grade serous carcinomas are not associated with an obvious point of initiation in the fallopian tube. The pathologist sits squarely in the midst of all of these issues, and has a pivotal role in managing expectations for stemming the death rate from this lethal disease.

Entities:  

Mesh:

Year:  2017        PMID: 28106106     DOI: 10.1038/modpathol.2016.238

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  67 in total

1.  Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.

Authors:  James R Conner; Emily Meserve; Ellen Pizer; Judy Garber; Michael Roh; Nicole Urban; Charles Drescher; Bradley J Quade; Michael Muto; Brooke E Howitt; Mark D Pearlman; Ross S Berkowitz; Neil Horowitz; Christopher P Crum; Colleen Feltmate
Journal:  Gynecol Oncol       Date:  2013-12-12       Impact factor: 5.482

2.  Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum.

Authors:  Naveena Singh; C Blake Gilks; Nafisa Wilkinson; W Glenn McCluggage
Journal:  Histopathology       Date:  2015-03-31       Impact factor: 5.087

3.  Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

Authors:  C Bethan Powell; Lee-may Chen; Jane McLennan; Beth Crawford; Charles Zaloudek; Joseph T Rabban; Dan H Moore; John Ziegler
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

4.  Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.

Authors:  Joseph W Carlson; Elke A Jarboe; David Kindelberger; Marisa R Nucci; Michelle S Hirsch; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2010-07       Impact factor: 2.762

5.  BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?

Authors:  Ilana Cass; Christine Holschneider; Nandini Datta; Denise Barbuto; Ann E Walts; Beth Y Karlan
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

6.  Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.

Authors:  Lucy Gilbert; Olga Basso; John Sampalis; Igor Karp; Claudia Martins; Jing Feng; Sabrina Piedimonte; Louise Quintal; Agnihotram V Ramanakumar; Janet Takefman; Maria S Grigorie; Giovanni Artho; Srinivasan Krishnamurthy
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

7.  Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.

Authors:  Marián Novak; Jenny Lester; Alison M Karst; Vinita Parkash; Michelle S Hirsch; Christopher P Crum; Beth Y Karlan; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2015-07-20       Impact factor: 5.482

8.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

9.  Incidental Serous Tubal Intraepithelial Carcinoma and Non-Neoplastic Conditions of the Fallopian Tubes in Grossly Normal Adnexa: A Clinicopathologic Study of 388 Completely Embedded Cases.

Authors:  Jeffrey D Seidman; Jayashree Krishnan; Anna Yemelyanova; Russell Vang
Journal:  Int J Gynecol Pathol       Date:  2016-09       Impact factor: 2.762

10.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Authors:  Ian J Jacobs; Usha Menon; Andy Ryan; Aleksandra Gentry-Maharaj; Matthew Burnell; Jatinderpal K Kalsi; Nazar N Amso; Sophia Apostolidou; Elizabeth Benjamin; Derek Cruickshank; Danielle N Crump; Susan K Davies; Anne Dawnay; Stephen Dobbs; Gwendolen Fletcher; Jeremy Ford; Keith Godfrey; Richard Gunu; Mariam Habib; Rachel Hallett; Jonathan Herod; Howard Jenkins; Chloe Karpinskyj; Simon Leeson; Sara J Lewis; William R Liston; Alberto Lopes; Tim Mould; John Murdoch; David Oram; Dustin J Rabideau; Karina Reynolds; Ian Scott; Mourad W Seif; Aarti Sharma; Naveena Singh; Julie Taylor; Fiona Warburton; Martin Widschwendter; Karin Williamson; Robert Woolas; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

View more
  17 in total

1.  The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer.

Authors:  Hiroshi Kobayashi; Kana Iwai; Emiko Niiro; Sachiko Morioka; Yuki Yamada; Kenji Ogawa; Naoki Kawahara
Journal:  Biomed Rep       Date:  2017-07-27

Review 2.  Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?

Authors:  Thomas Boerner; Kara Long Roche
Journal:  J Minim Invasive Gynecol       Date:  2020-10-08       Impact factor: 4.137

Review 3.  Advancements in Microfluidic Systems for the Study of Female Reproductive Biology.

Authors:  Vedant V Bodke; Joanna E Burdette
Journal:  Endocrinology       Date:  2021-10-01       Impact factor: 4.736

4.  Ovarian Mesonephric-like Adenocarcinoma With Multifocal Microscopic Involvement of the Fimbrial Surface: Potential for Misdiagnosis of Tubal Intraepithelial Metastasis as Serous Tubal Intraepithelial Carcinoma Associated With Ovarian High-grade Serous Carcinoma.

Authors:  Hyunjin Kim; Go Eun Bae; Yoon Yang Jung; Hyun-Soo Kim
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

5.  TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.

Authors:  Tomoko Akahane; Kenta Masuda; Akira Hirasawa; Yusuke Kobayashi; Arisa Ueki; Miho Kawaida; Kumiko Misu; Kohei Nakamura; Shimpei Nagai; Tatsuyuki Chiyoda; Wataru Yamagami; Shigenori Hayashi; Fumio Kataoka; Kouji Banno; Kokichi Sugano; Hajime Okita; Kenjiro Kosaki; Hiroshi Nishihara; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2022-03-21       Impact factor: 4.756

Review 6.  Ovarian cancer stem cells: still an elusive entity?

Authors:  Michela Lupia; Ugo Cavallaro
Journal:  Mol Cancer       Date:  2017-03-20       Impact factor: 27.401

7.  High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis.

Authors:  Yuichiro Hatano; Shinya Fukuda; Hiroshi Makino; Hiroyuki Tomita; Ken-Ichirou Morishige; Akira Hara
Journal:  Diagn Pathol       Date:  2018-04-27       Impact factor: 2.644

8.  LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.

Authors:  Elisa Schmoeckel; Ashley A Odai-Afotey; Michael Schleißheimer; Miriam Rottmann; Andrea Flesken-Nikitin; Lora H Ellenson; Thomas Kirchner; Doris Mayr; Alexander Yu Nikitin
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

9.  IGF-axis confers transformation and regeneration of fallopian tube fimbria epithelium upon ovulation.

Authors:  Che-Fang Hsu; Hsuan-Shun Huang; Pao-Chu Chen; Dah-Ching Ding; Tang-Yuan Chu
Journal:  EBioMedicine       Date:  2019-03-07       Impact factor: 8.143

10.  Sub-millimeter endoscope demonstrates feasibility of in vivo reflectance imaging, fluorescence imaging, and cell collection in the fallopian tubes.

Authors:  Ricky Cordova; Kelli Kiekens; Susan Burrell; William Drake; Zaynah Kmeid; Photini Rice; Andrew Rocha; Sebastian Diaz; Shigehiro Yamada; Michael Yozwiak; Omar L Nelson; Gustavo C Rodriguez; John Heusinkveld; Ie-Ming Shih; David S Alberts; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2021-07       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.